Original article by Sarah-Jane Tasker
The Australian – Page: 21 : 24-Mar-16

Australian-listed Sigma Pharmaceuticals has posted a 2015 net profit of $A50.5m, which is 4.3 per cent lower than previously, although revenue rose by 10 per cent to $A3.5bn. CEO Mark Hooper notes that the proportion of Sigma’s revenue from the Pharmaceutical Benefits Scheme has fallen in recent years due to the group’s push to diversify its sources of income. He has flagged acquisitions and identified expansion into the hospital pharmacy sector as a key growth strategy.

CORPORATES
SIGMA PHARMACEUTICALS LIMITED – ASX SIP